Natalie Mount
InvestorVenture Partner at Abingworth
About
Natalie Mount joined Abingworth as a Venture Partner in August 2022. She previously served as CEO of Adaptate Biotherapeutics and CSO of GammaDelta Therapeutics, both Abingworth-founded companies, and was a founding team member and Chief Clinical Officer at the Cell and Gene Therapy Catapult. Earlier she spent 16 years at Pfizer leading development activities including cell-based therapies in its Regenerative Medicine Unit. She holds a degree in Natural Sciences from the University of Cambridge and a Ph.D. from University College London.
Invests in
Biotech
Deals · 1
Allotera Therapeutics, Inc.Board seat
via Abingworth · filed Jul 2026 · $163M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Abingworth
Alex Asquith
Counsel at Abingworth
Andrew Sinclair
Managing Director, Head of Publics & Late Stage at Abingworth
Ankur Shah
Vice President, CCD at Abingworth
Anna Slezak
Senior Associate at Abingworth
Bali Muralidhar
Global Head of Life Sciences & CIO at Abingworth
Carlos Paya
Venture Partner at Abingworth
Dayle Hogg
Operating Executive at Abingworth
Diya Malhotra
Principal at Abingworth